Refractory portal hypertension complications successfully managed by parallel transjugular intrahepatic portosystemic shunt (TIPS): a case report

Senali Weeratunga¹, Mithun Nambiar¹², Charles Handley¹³, Cosmin Florescu¹, Stuart M. Lyon¹, Suong Le⁴³ and Diederick W. De Boo¹*

Abstract

Background: Transjugular intrahepatic portosystemic shunt (TIPS) is an established intervention to treat complicated portal hypertension refractory to medical or endoscopic management. TIPS dysfunction results in the recurrence of portal hypertension symptoms. In cases of TIPS dysfunction or persistent portal hypertension despite a patent primary TIPS, the creation of parallel TIPS may be the only intervention to effectively reduce portal pressure. Since the introduction of dedicated TIPS stents (Viatorr®) the incidence of TIPS dysfunction has reduced profoundly. Nevertheless, the creation of a parallel TIPS can still be necessary in the current dedicated TIPS stent era.

Case presentation: We report one such patient who experienced ongoing portal hypertension induced upper gastro-intestinal haemorrhage despite multiple TIPS revisions and a patent primary TIPS.

Conclusion: Following creation of a parallel TIPS, the patient remains in clinical remission with no further bleeding.

Keywords: TIPS, Interventional, Portal hypertension, Parallel shunt

Background

Transjugular intrahepatic portosystemic shunt (TIPS) is recommended and highly effective in appropriately selected patients with complications of portal hypertension such as refractory ascites, hydrothorax or severe variceal bleeding. TIPS dysfunction commonly results from shunt stenosis, occlusion or insufficient reduction in portosystemic gradient (PSG). This may be managed through balloon angioplasty, relining with stents or by extending the TIPS. (Alwarraky et al. 2020) In the event of ongoing portal hypertension complications with a patent primary TIPS or persistent TIPS dysfunction that is not amenable to recanalization, creation of a parallel TIPS is considered a technically challenging but viable alternative to achieve portal decompression. (Alwarraky et al. 2020) We report a patient who was successfully treated with parallel TIPS insertion for ongoing portal hypertension induced upper gastro-intestinal haemorrhage despite a patent primary TIPS and PSG under 10 mmHg.

Case presentation

A 55-year-old female with a history of bipolar affective disorder and type 2 diabetes mellitus presented to the emergency department with haematemesis and melaena secondary to variceal haemorrhage. The patient was hypotensive and tachycardic with a serum haemoglobin of 71 g/L. Abdominal ultrasound showed a cirrhotic liver, with a subsequent diagnosis of non-alcoholic steatohepatitis cirrhosis complicated by variceal

* Correspondence: Diederick.DeBoo@monashhealth.org
¹Monash Imaging, Monash Medical Centre, Clayton, Victoria, Australia

Full list of author information is available at the end of the article

© The Author(s). 2022 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
haemorrhage. At initial presentation the patient was categorised as Child Pugh A with a model for end-stage liver disease (MELD) score of 10.

Gastroscopy demonstrated grade I oesophageal varices and a large clot in the gastric fundus. A Sengstaken-Blakemore tube was inserted but failed to achieve haemostasis. Following a multidisciplinary team discussion, the patient was referred for TIPS creation. The shunt was created from the proximal right hepatic vein to the left portal vein with a Viatorr stent (Gore, Flagstaff AR, USA) extending to the hepatocaval junction, dilated to 9 mm (Fig. 1). A large coronary vein was also embolised.

The patient re-presented two months later with acute variceal bleeding due to TIPS thrombosis. After balloon angioplasty failed to restore flow, the TIPS was re-lined and extended further into the portal vein (Fig. 2). Residual coronary veins were embolised via the TIPS and the patient was commenced on prophylactic direct oral anticoagulation (Apixaban).

In the months following, the patient experienced ongoing bleeding from severe portal hypertensive gastropathy despite a total of three TIPS revisions and two gastric variceal embolisations. During this period the PSG never exceeded 10 mmHg. Following MDT review, she was referred for parallel TIPS. The existing TIPS was noted to be patent with a PSG of 9 mmHg prior to creation of the parallel TIPS from the right hepatic vein to the right main portal vein. A Viatorr TIPS stent (8 cm PTFE-covered, 2 cm bare metal) (Gore, Flagstaff, USA) was inserted and dilated to 8 mm, reducing the PSG to 4 mmHg (Fig. 3).

The patient had an uneventful recovery with no immediate or delayed hepatic encephalopathy. Ultrasonography at both seven days and 5 months as well as MRI ten months post-procedure demonstrated patent parallel and primary TIPS. At ten months post-intervention, she remains well with no further bleeding or hepatic encephalopathy.

This study, being a case report, did not require institutional review board approval at the participating institution. Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

**Discussion**

TIPS is considered mainstay in managing complications from portal hypertension. However, ever since the first TIPS in 1969, the long-term efficacy of the intervention has been impeded by shunt dysfunction. (Rösch et al. 1969) The introduction of PTFE-covered stents replacing the use of bare metal stents has significantly improved longevity, yet patients often require multiple revisions of their TIPS (Triantafyllou et al. 2018). The major causes of bare metal stent TIPS dysfunction are in-stent thrombosis, intimal hyperplasia of the outflow hepatic vein and pseudointimal hyperplasia within the shunt lumen caused by biliary leakage from disrupted bile ducts. (Fanelli 2014) This may manifest as variceal bleeding, ascites, hydrothorax or hepatic encephalopathy, secondary to portal hypertension.

Parallel TIPS was first reported by Dabos et al. in 1998, prior to the availability of dedicated covered TIPS stents. The study assessed balloon angioplasty, restenting and creation of a parallel TIPS as interventions for TIPS dysfunction, recommending parallel TIPS for patients with early shunt dysfunction or severe recurrent pseudointimal hyperplasia. (Dabos et al. 1998) Parallel TIPS has since been predominantly reserved for when the primary TIPS is inaccessible or unfavourable for re-canalization and for persisting portal hypertension despite verified patency on imaging. (Raisi et al. 2019) It has demonstrated similar patency rates in the mid-term compared to TIPS of patients who do not undergo parallel TIPS. (Raisi et al. 2019; Helmy et al. 2006)

Aside from the introduction of dedicated, covered TIPS stents, several factors contribute to maximising
TIPS function. Some reports have suggested that entry of the stent at the left portal vein branch, compared to the right, is associated with improved longevity due to the straighter trajectory to the hepatic vein that allows for less turbulent blood flow. Puncturing the left portal vein may be more technically difficult given its location relative to the inferior vena cava. (Alwarraky et al. 2020; Chen et al. 2009; Luo et al. 2019; Chu et al. 2002) A study by Clark et al. also demonstrated longer patency in stents that extend to the hepatocaval junction rather than those terminating at the hepatic vein. (Clark et al. 2004) The TIPS stent in our patient terminated at the hepatic vein which could have contributed to the early stent occlusion in just over two months, requiring relining of the stent and commencement of apixaban. The use of prophylactic anticoagulation and antiplatelet therapy can reduce the incidence of both TIPS stenosis as well as de novo portal vein thrombosis occurring after TIPS. However, this carries the increased risk of rebleeding from varices. As such, certain patients may benefit from variceal embolization alongside parallel TIPS creation. (Tang et al. 2017)

He et al. describe a cohort of 10 patients undergoing parallel TIPS with non-TIPS-dedicated covered stents. (He et al. 2014) Nine patients suffered from persistent ascites and one patient had ongoing variceal bleeding...
despite patent primary TIPS. Reduction in PSG occurred in all patients, as well as clinical remission from portal hypertensive symptoms.

There is limited literature on parallel TIPS in which Viatorr® stents, dedicated covered TIPS stents, are used for both procedures. One case report describes a patient with alcoholic cirrhosis who had two TIPS revisions before a parallel TIPS was inserted from the right hepatic to right portal vein. The PSG was reduced from 10 mmHg to 5 mmHg, however no follow-up data was included to describe the longevity of the parallel TIPS. (Larson et al. 2016) Another study reported two patients who experienced recurrent ascites, hydrothorax and elevated PSG despite venography indicating a patent primary TIPS. Both individuals demonstrated clinical improvement after parallel TIPS creation. (Parvinian and Gaba 2013) More recently, a case series by Raissi et al. followed three patients with failed endoscopic management of variceal bleeding after initial TIPS placement. Two of these patients also had patent TIPS and a PSG below 10 mmHg prior to parallel shunt insertion, comparable to our patient. (Raissi et al. 2019) Our findings concur with these latter two reports, suggesting that shunt patency may not necessarily correlate with the clinical features of TIPS dysfunction that necessitate parallel TIPS creation.

Hepatic encephalopathy is the most common complication of parallel TIPS. In most cases, this is adequately controlled with medical management. Rarer complications include biliary puncture, intraperitoneal haemorrhage and hepatic failure. (Alwarraky et al. 2020; Raissi et al. 2019) Overall, however, the parallel TIPS is considered a safe intervention for managing refractory portal hypertension, with a similar safety and adverse effect profile to a primary TIPS.

Conclusion

Parallel TIPS still has a place in the management of persistent complications of portal hypertension in patients with patent primary TIPS created with dedicated, covered Viatorr® TIPS stents and a porto-systemic gradient below 10 mmHg.

Abbreviations

TIPS: Transjugular intrahepatic porta-systemic shunt; PSG: Porta-systemic gradient; MELD: Model for end stage liver disease; PTFE: Polytetrafluoroethylene

Acknowledgements

Not applicable.

Authors’ contributions

Authors SW and MN contributed to the writing process and original draft preparation. Authors DDB, CH, CF, S. Lyon and S. Le contributed to the conceptualisation of the project as well as review and editing of the final manuscript. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

This study did not require institutional review board approval at the participating institution.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Competing interests

The authors declare that they have no competing interests.

Author details

1Monash Imaging, Monash Medical Centre, Clayton, Victoria, Australia.
2Faculty of Medicine, Nursing and Health Science, Monash University, Clayton, Victoria, Australia. 3School of Clinical Sciences, Monash University, Clayton, Victoria, Australia. 4Department of Gastroenterology and Hepatology, Monash Health, Clayton, Victoria, Australia.

Received: 14 February 2022 Accepted: 8 April 2022

Published online: 18 April 2022

References

Alwarraky MS, Elzohary HA, Meleagy MA, Mohamed A (2020) Parallel transjugular intrahepatic portosystemic shunt (TIPS) for TIPS dysfunction: technical and patency outcome. Egypt J Radiol Nucl Med 51(1):1–9. https://doi.org/10.1016/j.ejrm.2020.02.003
Chen L, Xiao T, Chen W, Long Q, Li R, Fang D, Wang R (2009) Outcomes of transjugular intrahepatic portosystemic shunt through the left branch vs. the right branch of the portal vein in advanced cirrhosis: a randomized trial. Liver Int 29(7):1101–1109. https://doi.org/10.1111/j.1478-3231.2009.01916.x
Chu J, Sun X, Piao L, Chen Z, Huang H, Lu C, Xu J (2002) Portosystemic shunt via the left branch of portal vein for the prevention of encephalopathy following transjugular intrahepatic portosystemic shunt. Zhonghua Gan Zang Bing Za Zhi 10(6):437–440
Clark TWI, Agarwal R, Haskal ZJ, Stavropoulos SW (2004) The effect of initial shunt outflow position on patency of transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 15(2):147–152. https://doi.org/10.1097/01.RVI.0000109401.52762.56
Dabos KJ, Stanley AJ, Redhead DN, Jalan R, Hayes RC (1998) Efficacy of balloon angioplasty, restenting, and parallel shunt insertion for shunt insufficiency after transjugular intrahepatic portosystemic stent-shunt (TIPS), Minim Invasive Ther Allied Technol 7(3):287–293. https://doi.org/10.3109/13645709809152867
Farrell F (2014) The evolution of Transjugular intrahepatic portosystemic shunt: Tips. ISRN Hepatol 2014:1–12. https://doi.org/10.1155/2014/762096
He FL, Wang L, Yue ZD, Zhao HW, Liu FQ (2014) Parallel transjugular intrahepatic portosystemic shunt-shunt for controlling portal hypertension complications in cirrhotic patients. World J Gastroenterol 20(33):11825–11839. https://doi.org/10.3748/wjg.v20.i33.11835
Helmy A, Redhead DN, Stanley AJ, Hayes PC (2006) The natural history of parallel transjugular intrahepatic portosystemic stent shunts using uncovered stents: the role of host-related factors. Liver Int 26(5):572–578. https://doi.org/10.1111/j.1478-3231.2006.01264.x
Larson M, Kirsch D, Kay D (2016) Parallel transjugular intrahepatic portosystemic shunt (TIPS) in the setting of TIPS occlusion. Ochsner J 16(2):113–115
Luo SH, Chu JG, Huang H, Zhao GR, Yao KC (2019) Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy. World J Gastroenterol 25(9):1088–1099. https://doi.org/10.3748/wjg.v25.i9.1088
Parvinian A, Gaba RC (2013) Parallel TIPS for treatment of refractory ascites and hepatic hydrothorax. Dig Dis Sci 58(10):3052–3056. https://doi.org/10.1007/s10620-013-2688-8
Raissi D, Yu Q, Nisieiwicz M, Krohmer S (2019) Parallel transjugular intrahepatic portosystemic shunt with Viatorr® stents for primary TIPS insufficiency: case
series and review of literature. World J Hepatol 11(2):217–225. https://doi.org/10.4254/wjh.v11.i2.217
Rösch J, Hanafee WN, Snow H (1969) Transjugular portal venography and radiologic portacaval shunt: an experimental study. Radiology 92(3):1112–1114. https://doi.org/10.1148/92.3.1112
Tang Y, Zheng S, Yang J, Bao W, Yang L, Li Y, Xu Y, Yang J, Tong Y, Gao J, Tang C (2017) Use of concomitant variceal embolization and prophylactic antiplatelet/anticoagulative in transjugular intrahepatic portosystemic shunting: a retrospective study of 182 cirrhotic portal hypertension patients. Med (United States) 96(49):e8678. https://doi.org/10.1097/MD.0000000000008678
Triantafyllou T, Aggarwal P, Gupta E, Svetanoff WJ, Bhirud DP, Singhal S (2018) Polytetrafluoroethylene-covered stent graft versus bare stent in transjugular intrahepatic portosystemic shunt: systematic review and meta-analysis. J Laparoendosc Adv Surg Tech 28(7):867–879. https://doi.org/10.1089/lap.2017.0560

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.